A new dosing regimen for Kisunla, to help lower the risk of certain side effects, has been approved by the U.S. Food and Drug ...

The patients were randomly assigned to either 50 or 100 mg of simufilam as oral tablets or a placebo twice daily for about a year and a half. The main goals included watching for changes in both ...

Women see higher risk, faster disease progression Alzheimer’s does not affect the sexes equally. Not only are women at a higher risk of the disease, but they tend to experience faster disease ...

Data from Study 201 demonstrated that stopping Leqembi treatment led to a reaccumulation of amyloid-beta in the brain and reversal of cognitive benefits. The now-approved regimen means patients who ...

The company recently announced results from two Phase 3 trials testing AXS-05. One study, ACCORD-2, hit its main goal while the other, ADVANCE-2, didn’t. Axsome said it will use data from these trials ...

The test, developed by Roche in collaboration with Eli Lilly, is intended to support a more accurate Alzheimer’s diagnosis in adults, ages 60 and older, when used with other clinical assessments.

The global Phase 2b/3 trial, called Anavex 2-73-AD-004 (NCT03790709), enrolled 509 people, ages 60-85, with mild cognitive impairments or mild dementia due to Alzheimer’s. The participants were ...

TRANQUILITY II trial finds BXCL501 safe, effective, well tolerated Dexmedetomidine, the active agent in BXCL501, works to activate certain brain proteins, known as alpha-2a adrenergic receptors, which ...

“Results of our open-label proof-of-concept study with COYA 301 in 8 patients with Alzheimer’s showed encouraging results,” Howard Berman, PhD, Coya’s CEO, said in an emailed statement to Alzheimer’s ...

With this approval, Rexulti has now become the first and only therapy ever approved for this specific indication in the U.S. “Today marks a major milestone for patients, caregivers, and families ...

The Phase 1b portion was a one-month ascending dose phase to assess its safety, tolerability, and pharmacological properties. In the Phase 2 efficacy portion, participants were randomly assigned ...

That’s according to top-line data from the open-label Phase 2 study (NCT04388254) in 216 people with mild-to-moderate disease, treated with simufilam tablets at 100 mg twice daily for a year. A ...